{"id":10318,"date":"2020-10-20T12:00:00","date_gmt":"2020-10-20T17:00:00","guid":{"rendered":"https:\/\/shockwavemedical.com\/news\/shockwave-disrupt-pad-iii-results-to-be-presented-in-late-breaking-session-at-viva20\/"},"modified":"2020-10-20T12:00:00","modified_gmt":"2020-10-20T17:00:00","slug":"shockwave-disrupt-pad-iii-results-to-be-presented-in-late-breaking-session-at-viva20","status":"publish","type":"news","link":"https:\/\/shockwavemedical.com\/en-eu\/news\/shockwave-disrupt-pad-iii-results-to-be-presented-in-late-breaking-session-at-viva20\/","title":{"rendered":"Shockwave Disrupt PAD III Results to be Presented in Late-Breaking Session at VIVA20"},"content":{"rendered":"\n
\n\t
\n\t\t

SANTA CLARA, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) \u2014 Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the acute results from the DISRUPT PAD III randomized study have been accepted for presentation in a late-breaking session at VIVA20, being held virtually from November 6-8, 2020.<\/p>\n

\u201cDISRUPT PAD III is the largest randomized study of severely calcified peripheral lesions ever conducted and includes patients who have generally been excluded from previous peripheral trials. As such, these data will provide important new insights on optimizing vessel preparation for challenging lesions in a core lab adjudicated randomized study,\u201d said Keith D. Dawkins, M.D., Chief Medical Officer of Shockwave Medical. \u201cOn behalf of the entire Shockwave team, I want to thank all of the investigators, research coordinators and patients who have supported this study. We look forward to the acute safety and effectiveness results being shared at VIVA20.\u201d<\/p>\n

The details of the late-breaking session are as follows:<\/p>\n\n\n\n\n\n
Presentation Title:<\/td>\nDISRUPT <\/strong>P<\/strong>AD III<\/strong>\u00a0RCT Acute Results: IVL vs PTA in Severe Calcium<\/strong><\/td>\n<\/tr>\n
Time:<\/td>\nNovember 7, 2020 at 7:00 am Pacific Time<\/td>\n<\/tr>\n
Presenter:<\/td>\nDr. William (Bill) Gray, M.D., FACC, FSCAI, Chief of the Division of Cardiovascular Disease at Main Line Health, Wynnewood, PA; Co-Principal Investigator of DISRUPT PAD III<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/p>\n

Also occurring on November 7, 2020 at VIVA20, Professor Andrew Holden, MBChB, Auckland City Hospital, Auckland New Zealand, will host\u00a0T<\/em>he\u00a0<\/em>Shockwave Symposium: Insights from the DISRUPT PAD III RCT in Severe Calcium<\/em>, an expert panel discussion of perspectives on the DISRUPT PAD III data. The event is scheduled for 9:50 am Pacific Time.<\/p>\n

About DISRUP<\/strong>T<\/strong>\u00a0P<\/strong>AD III\u00a0<\/strong><\/p>\n

DISRUPT PAD III is a prospective, multicenter, randomized post-market study designed to demonstrate the safety and effectiveness of the Shockwave Peripheral IVL Catheter as a vessel preparation tool in moderate to severely calcified superficial femoral and popliteal artery lesions. The study enrolled 306 patients. Patients were enrolled at 45 sites in the United States, Germany, Austria and New Zealand. Patients will be followed for two years.<\/p>\n

The primary endpoint is procedural success defined as residual stenosis less or equal to than 30 percent without flow-limiting dissection (greater or equal to Grade D) The primary endpoint was assessed by an angiographic core lab after vessel preparation and post-dilatation, if required, and prior to DCB or stent placement.<\/p>\n

The co-principal investigators of the study were William A. Gray, M.D. and Gunnar Tepe, M.D., Head of the Department of Diagnostic and Interventional Radiology, RoMed Clinic Rosenheim, Germany.<\/p>\n

A<\/strong>bout Shockwave Medical, Inc.\u00a0<\/strong><\/p>\n

Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit\u00a0www.shockwavemedical.com<\/a>.<\/p>\n

Forward-Looking Statements<\/strong>
\nThis press release contains statements relating to our expectations, projections, beliefs, and prospects, including statements regarding our product development outlook, which are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential\u201d or \u201ccontinue,\u201d and similar expressions, and the negative of these terms. Such forward-looking statements are subject to risks, uncertainties, and assumptions about us and are not guarantees of future performance. You are cautioned not to place undue reliance on these forward-looking statements.<\/p>\n

Forward-looking statements contained in this press release may include, but are not limited to, statements about: the impact of the\u00a0COVID-19\u00a0pandemic on our operations, financial results, and liquidity and capital resources, including on our sales, expenses, supply chain, manufacturing, research and development activities, clinical trials and employees; our ability to design, develop, manufacture and market innovative products to treat patients with challenging medical conditions, particularly in peripheral artery disease, coronary artery disease and aortic stenosis; our expected future growth, including growth in international sales; the size and growth potential of the markets for our products, and our ability to serve those markets; the rate and degree of market acceptance of our products; coverage and reimbursement for procedures performed using our products; the performance of third parties in connection with the development of our products, including third-party suppliers; regulatory developments in\u00a0the United States\u00a0and foreign countries; our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines; our plans to research, develop and commercialize our products and any other approved or cleared product; our ability to scale our organizational culture of cooperative product development and commercial execution; the development, regulatory approval, efficacy and commercialization of competing products; the loss of key scientific or management personnel; our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; our ability to develop and maintain our corporate infrastructure, including our internal controls; our financial performance and capital requirements; and our expectations regarding our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others.<\/p>\n

These forward-looking statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. These factors, as well as others, are discussed in our filings with the\u00a0Securities and Exchange Commission\u00a0(SEC), including in Part I, Item IA \u2013 Risk Factors in our most recent Annual Report on Form 10-K filed with the\u00a0SEC, and in our other periodic and other reports filed with the\u00a0SEC. Forward-looking statements we make are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date of this press release to conform these statements to actual results or revised expectations.<\/p>\n

Media Contact:<\/strong>
\nScott Shadiow
\n+1.317.432.9210
\nsshadiow@shockwavemedical.com<\/a><\/p>\n

Investor Contact:<\/strong>
\nDebbie Kaster
\ndkaster@shockwavemedical.com\u00a0<\/a><\/p>\n\t<\/div>\n\t<\/section>","protected":false},"excerpt":{"rendered":"

The acute results from the DISRUPT PAD III randomized study have been accepted for presentation in a late-breaking session at VIVA20.<\/p>\n","protected":false},"featured_media":9294,"template":"","format":[],"meta":{"_acf_changed":true,"content-type":""},"disease-state":[],"news-topic":[],"product-tag":[],"specialty":[],"technology":[324],"class_list":["post-10318","news","type-news","status-publish","has-post-thumbnail","hentry","technology-peripheral-ivl-en-uk"],"acf":[],"_links":{"self":[{"href":"https:\/\/shockwavemedical.com\/en-eu\/wp-json\/wp\/v2\/news\/10318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/shockwavemedical.com\/en-eu\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/shockwavemedical.com\/en-eu\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/shockwavemedical.com\/en-eu\/wp-json\/wp\/v2\/media\/9294"}],"wp:attachment":[{"href":"https:\/\/shockwavemedical.com\/en-eu\/wp-json\/wp\/v2\/media?parent=10318"}],"wp:term":[{"taxonomy":"disease-state","embeddable":true,"href":"https:\/\/shockwavemedical.com\/en-eu\/wp-json\/wp\/v2\/disease-state?post=10318"},{"taxonomy":"format","embeddable":true,"href":"https:\/\/shockwavemedical.com\/en-eu\/wp-json\/wp\/v2\/format?post=10318"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/shockwavemedical.com\/en-eu\/wp-json\/wp\/v2\/news-topic?post=10318"},{"taxonomy":"product-tag","embeddable":true,"href":"https:\/\/shockwavemedical.com\/en-eu\/wp-json\/wp\/v2\/product-tag?post=10318"},{"taxonomy":"specialty","embeddable":true,"href":"https:\/\/shockwavemedical.com\/en-eu\/wp-json\/wp\/v2\/specialty?post=10318"},{"taxonomy":"technology","embeddable":true,"href":"https:\/\/shockwavemedical.com\/en-eu\/wp-json\/wp\/v2\/technology?post=10318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}